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Abstract Carbon nanoparticles (CNPs) labeled with
reporter molecules can serve as signaling labels in rapid
diagnostic assays as an alternative to gold, colored
latex, silica, quantum dots, or up-converting phosphor
nanoparticles. Detailed here is the preparation of
biomolecule-labeled CNPs and examples of their use
as a versatile label. CNPs can be loaded with a range of
biomolecules, such as DNA, antibodies, and proteins (e.g.,
neutravidin or a fusion protein of neutravidin with an
enzyme), and the resulting conjugates can be used to detect
analytes of high or low molecular mass.
Keywords Carbon nanoparticles . Lateral flow assays .
Protein microarray-based assays . Nucleic acid
immunoassays (DNA/RNA) . Immunochemical assays .
Diagnostics
Abbreviations
CNPs Carbon nanoparticles
CNTs Carbon nanotubes
LFIA Lateral flow immunoassay
NALFIA Nucleic acid lateral flow immunoassay
NALMIA Nucleic acid lateral flowmicroarray immunoassay
NAMIA Nucleic acid microarray immunoassay
Introduction
Modern analytical methods include, among others,
immunochemical and DNA/RNA hybridization-based
techniques. Such techniques rely on the molecular
recognition of antigens by their corresponding anti-
bodies or on the recognition of complementary DNA/
RNA sequences, respectively. To visualize the interac-
tion, a label of one kind or another must be attached to
either the antigen or the antibody. Rapid assay formats
have emerged at the point of care/need, and the lateral
flow assay (LFA) format is very well suited to this
purpose, and thus often used [1]. For this assay format,
particulate labels with optical properties are obligatory for
visual inspection. The use of nanoparticles as a label has
been discussed in recent reviews [2, 3], but the utilization
of elemental carbon as a label has not been mentioned
aside from a chapter in the book Using Nanoparticles in
Agricultural and Food Diagnostics [4].
Among these particulate labels, it was shown in a
literature survey by the independent FIND Diagnostics
organization that when CNPs are used as labels in the LFA
format, they are more sensitive than gold or latex [5].
Sensitivity in the low picomolar range was reported for
carbon nanoparticles (CNPs), even by visual inspection.
Moreover, CNPs are the cheapest labels, and suspensions of
them are very stable and easy to prepare. In addition, no
activation is necessary. We will stress the difference
between carbon nanoparticles—which are amorphous—
and carbon nanotubes (CNTs), which have a defined
structure (i.e., single- and multi-walled nanotubes). These
CNTs are mainly used in pre-concentration systems, as
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reviewed in [6], and as labels in electrochemical systems, as
reviewed in [7]. The use of CNTs in diagnostics will not be
discussed here, as a general review of the use of CNTs as
detection labels has recently been published [8].
Instead, we will present the preparation, functionaliza-
tion, and use of carbon nanoparticles as labels in diagnostic
assays such as in LFAs and in antibody microarray formats.
An overview of their strengths and weaknesses is given in
Table 1, and an overview of opportunities and threats
associated with them is shown in Table 2.
Preparation and functionalization
CNPs can be obtained from soot, commercially available
from different sources. These preparations are intended for
other uses, such as in toner or ink for printers or in
automobile tires. Type SB4 (Special Black 4) from the
company Degussa AG was reported as a label at first in
1993 [9]. This type receives special post-treatment in order
to generate a few aldehyde groups, and does not need a
stabilizer in suspension to obtain colloidally stable plain
nanoparticles [10, 11]. Accordingly, the preparation of
aqueous suspensions and the functionalization of the nano-
particles are easy tasks. For some applications, a shortcom-
ing of this type is that the particles are not monodisperse in
nature, as can be seen in Fig. 1, although uniform sizes can
be obtained, which are called carbon nanostrings [12].
Although this heterogeneous size distribution may be a
drawback, in most applications it is a clear advantage (see
below).
The number of functional groups on these nanoparticles
is very small, precluding the possibility of the covalent
attachment of proteins or DNA. However, physical adsorp-
tion has the advantage that, in most cases, the specificity is
retained. Achieving a specific orientation, which is useful
for presenting binding/active domains of antibodies or
enzymes to the liquid phase, can be done with intermediary
biomolecules such as protein A, protein G, or a secondary
antibody.
Several other carbon brands need the presence of
stabilizers [10, 11]. Amongst these are preparations that
lead to monodisperse particles in stable suspensions, e.g.,
after treatment using a ball mill [13].
Soot obtained by burning toluene was claimed to have a
surface that could be covalently attached to streptavidin,
Table 1 SWOT analysis of CNPs: internal factors
Strengths Weaknesses
Inert in terms of surface charge, relatively independent of pH, does
not oxidize
Low density: not really suitable for TEM/SEM
Amorphous carbon is suitable for physical adsorption due to
hydrophobic surface characteristics
Some types of carbon require the addition of surfactants to obtain
stable suspensions in aqueous media: such surfactants may interfere
with test performance
High contrast, good sensitivity The presence of larger, irregularly shaped carbon particles requires
the use of nitrocellulose with larger pore openings; the captured
ligand concentration/density is then relatively low, resulting in
"relatively diffuse" signal
Relatively large dynamic range: at high(er) concentrations, the small
(er) particles contribute to the signal, and at low(er) concentrations,
the large(r) particles provide the greatest contribution
Still relatively unknown label in commercial diagnostic tests and
in the literature
Relatively high molar extinction coefficient compared to latex; relatively
strong signals offer high test sensitivities (down to low picomolar
concentrations [5])
Elemental carbon covalent linkage through the targeted use of
reactive groups is problematic
A relatively low density, stable suspension of relatively large particles
is possible (also an advantage in terms of the response)
Fixed functionality; e.g., not paramagnetic, no change of color
Heterogeneous particle size distribution is less prone to the hook effect Luminescent CNPs need a more expensive readout system;
visualization is not possible
Carbon suspensions are easy to prepare
Good flow characteristics in the case of capillary migration
Label is available in large to very large batches, variation in quality/
features over time is negligible (especially in combination with inert
materials)
Label is obtainable at very low cost
Scaling up production after test preparation is a relatively simple task
Carbon “variants under Patents US5529901A1 [10] and
US5641689A1 [11]” do not require the addition of surfactants for
stable suspensions in aqueous media
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antibodies, or G-protein via glutaraldehyde coupling [14].
An average size of 162±52 nmwas recorded, and a stability of
over ten years was observed. However, the chemical reaction
that facilitated the covalent binding was unclear. CNPs were
prepared from fructose by hydrothermal degradation, and
subsequently functionalized by the covalent attachment of
enzyme-labeled anti α-fetoprotein [15].
CNPs prepared from other sources were reported to show
more homogeneous dimensions. These CNPs were prepared
from graphene oxide [16], carbohydrates [17–19], benzene
[20], or cyclodextrins [21]. The chemical modification steps
that yield nanoparticles with fluorescent, phosphorescent, or
up-converting properties (luminescent CNPs) are described
in [22–28].
However, these CNP preparation methods are all either
rather complex or they require expensive starting materials,
and they are often also made more expensive by the high
energy consumption of the process. Moreover, large-scale
preparation is often a serious problem. These disadvantages
were sidestepped by using raw carbon as starting material
and a one-step ultrasonic treatment in a hydroxide peroxide
solution [24], which produced enough active functional
groups for covalent attachment. This resulted in hydrophilic
nanoparticles with fluorescent, phosphorescent, and up-
converting properties that were 5–10 nm in size.
Applications to lateral flow assays (LFA)
Sandwich-type lateral flow immunoassays (LFIA)
In this kind of assay, the analyte is sandwiched between the
capture antibody (which has been sprayed at the test line of
the nitrocellulose strip) and the detection antibody (which
has been labeled for visualization). The analyte is usually a
molecule with a relatively high molecular mass, such as a
protein. The detection antibody can be immobilized onto
the CNPs by physical adsorption, thus generating an
immunolabel. As in other immunoassays, such as ELISAs,
the signal is proportional to the analyte concentration.
Applications include pregnancy test kits based on human
chorionic gonadotropin [29] (working range 5-300 mIU/mL);
verotoxin-producing Escherichia coli detection [30, 31]
(specificity in ring tests: 95–100%); the diagnosis of
schistosomiasis using circulating cathodic antigen in urine
[32] (specificity 90%), and the detection of fungal amylase in
the workplace [33, 34] (in a field test using wipes, 100%
agreement with an ELISA at allergen levels of >5 ng/mL
was observed). The results of these tests are mainly
interpreted visually, sometimes by comparison with a standard
set. The use of a flatbed scanner to quantify the response was
first mentioned in 2001 [35] for immunoglobulin E detection.
This assay showed enhanced sensitivity and yielded semi-
quantitative or even quantitative results.
In a survey performed by the Foundation for Innovative
New Diagnostics (FIND) in which the sensitivities of
immunolabels used in lateral flow assays were investigated,
CNPs were ranked in the top five, well above more
conventional labels such as gold and latex [5]. The
sensitivities of assays with CNPs were in the low pM
range, whether the results were interpreted visually or using
Table 2 SWOT analysis of CNPs: external factors
Opportunities Threats
Very well suited for use in lateral flow test systems where sensitivity is
associated with a relatively wide dynamic range
In the case of pollution: materials (tubing, measuring cells, devices)
are not easy to clean; carbon label is less suitable for use in complex,
expensive devicesDue to their high contrast, they are suitable for use as a label system in
antibody microarray formats
Because of “black on white” test results (applicable to nitrocellulose,
nylon, polystyrene colored white), very suitable for quantification
of results using "gray pixel" processing
Amorphous particles in the dry state during and immediately after
the production phase (present in bulk quantities) can be potentially
harmful to health, as they are fine particles; however, their utilization
as CNPs in immunoassays does not present health problems
Suitable for use as a label in agglutination/precipitation assays Finding carbon particles with the desired properties/characteristics
(e.g., particles with similar properties but that are much smaller
in size) is dependent on what the market can offer
Suitable for use in sensors that employ piezoelectric film detection/
sensing
Fig. 1 SEM image of Flammruss 101 (comparable to SB4); images
courtesy of Evonik-Degussa AG
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a flatbed scanner or digital camera. In this kind of assay, the
heterogeneity in particle size in the carbon suspension is an
advantage, as the smaller particles reach the test line more
rapidly than the larger particles. The hook effect—which
often affects immunochemical sandwich type assays [36]—
is clearly reduced, and the dynamic range of the lateral flow
assay is substantially increased by up to four orders of
magnitude, as shown in Fig. 2 (unpublished results).
The detection of p24 antigen from HIV-infected infants
was reported using an unspecified carbon black preparation
from Evonik Degussa Corporation (Parsippany, NJ, USA)
[37]. The sensitivity of this assay with pure recombinant
antigen was reported to be 50 pg/mL (2 pM). In infant
plasma, an overall sensitivity and a specificity of 90% and
100%, respectively, were achieved using a flatbed scanner
and a homemade MATLAB program to evaluate the results.
Isotyping of transferrin in serum was achieved using a
lateral flow test and CNPs [38]. An integrated setup
combining a separation membrane and a lateral flow strip
was used to detect carbohydrate-deficient transferrin.
Measured isoforms constituted a minimal part (0.3%) of
the total amount of transferrin. The measuring time was
about 10 min, and the correlation coefficient with an
established, commercial, two-step procedure, which
takes 4–5 h to perform, was 0.99 [38]. This group later
used carbon nanostrings to isotype transferrin isotypes in a
lab-on-a-chip setup with a lateral flow strip (pI differences
of 0.1 pH units could be successfully discriminated) [39].
Carbon nanostrings were also used to detect erythropoietin
in urine [12].
CNPs prepared from soot by burning toluene have been
used to develop several rapid assays [14]. Protein G
covalently attached to these particles was the intermediate
in an assay that was specific for HIV antigens [14], whereas
anti-human chorionic gonadotropin antibodies were used
for a pregnancy hormone-specific assay [14]. Covalent
attachment using CNPs prepared hydrothermally in a
closed system in the presence of fructose was reported for
the detection of α-fetoprotein using HRP-labeled anti
α-fetoprotein [15]. Very good sensitivity was obtained in an
electrical readout system using sheets of anti α-fetoprotein-
functionalized graphene on a graphite electrode.
Fig. 2 Large dynamic range of
a sandwich-type lateral flow
assay that shows a diminished
hook effect. hCG levels in
pregnant women may reach
concentrations of up to 50,000
mIU/mL at 8 weeks since the
last menstruation. Even at a
concentration ten times higher
than this (i.e., 500,000 mIU/
mL), there is still a positive
response. Upper panel: LFIA
strips (C control line, T test
line). Lower panel: graph based
on pixel gray volumes obtained
by flatbed scanning and
digitization
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Inhibition-type lateral flow immunoassays (LFIA)
In this kind of assay, the reagents consist of a specific antibody
and a carrier protein to which small analyte molecules (with a
low molecular mass; so-called haptens) have been covalently
bound. Both reagents can be used as either the detection or the
capture ligand, although in most cases the carrier protein–
analyte (hapten) conjugate is sprayed onto the nitrocellulose
membrane at the test line. The free analyte in the sample
competes with the carrier protein bound analytes for antibody
binding sites at the test line. Both the detection antibody and
the analyte–carrier protein conjugate are either immobilized
onto the nitrocellulose membrane or labeled onto the CNPs by
physical adsorption.
In another approach, a secondary antibody raised against
the animal species of the specific detection antibody is
coupled to the CNPs. This means that titration of the
specific antibody will give a 100% signal that can be easily
scored by visual inspection. This approach allows the
sensitivity of the inhibition-type immunoassay to be greatly
increased compared to tests in which the specific antibody
has been coupled onto the nanoparticles. Also, in this case the
response is negatively correlated to the amount of analyte.
Applications include the detection of sulfamethazine in urine
[40], progesterone in buffer [41], methiocarb in surface water
[42], and carbaryl and thiabendazole residues in fruit juices
[43, 44]. A typical example is depicted in Fig. 3.
Nucleic acid lateral flow (immuno)assays (NALF(I)A)
This technique was presented in the journal IVD Technology
[45] by the company Xtrana. The method relies on the
amplification of specific DNA or RNA sequences using
labeled primers. Nucleic acid lateral flow immunoassays
using carbon nanoparticles were first reported in 2005 for
the detection of Shiga toxin producing Escherichia coli
[46]. One primer was labeled with a discriminating tag, and
the other primer with a biotin moiety. Anti-discriminating
tag antibodies were immobilized onto the lateral flow strip
and neutravidin was adsorbed onto CNPs. After applying a
fast amplification protocol to the specific nucleic acid
sequences (30 min), a small amount of amplicon was added
to the CNP–neutravidin suspension, and it was then run on
the prepared NALFIA. Several applications show the
versatility of this procedure. Plasmodium falciparum species
were detected in sera of patients suffering from malaria [47];
also reported were the presence/absence of Listeria bacteria
in food (see Fig. 4) [48], and the detection of Cronobacter
spp. in baby food [49], and the presence of virulence factors
in Shiga-toxin producing Escherichia coli [50].
In another NALF approach, carbon nanostrings onto
which BSA had been physically adsorbed were applied.
The BSA molecules had been functionalized through the
covalent coupling of DNA oligonucleotide probes [51]. As
a proof of principle, the detection of the maize invertase
gene was reported. This gene can function as the reference
gene in maize when looking for genetically modified maize.
Also reported was the detection of a single nucleotide
polymorphism in the toll-like receptor 4 gene as a pathogen
recognition scheme, and the activation of innate immunity.
Applications of antibody microarray immunoassays
(MIA)
As well as creating assays in the LFA format, it is also
possible to print capture antibodies as very small spots in a
Fig. 4a–b Typical results from the simultaneous detection of L.
monocytogenes and generic Listeria spp. amplicons by agarose gel
electrophoresis (a) and NALFIA (b) after duplex PCR. For both a and
b, chromosomal DNA of L.monocytogenes (lane 1), L.innocua (lane
2), and Enterobacter cloacae (lane 3) were used for the duplex PCR.
The negative control (lane 4) is a primer control (PCR without
template DNA). Mr DNA size marker, TL1 test line specific to all
species from the genus Listeria (line with anti-FITC antibody), TL2
test line specific to L.monocytogenes (line with anti-DIG antibody).
Reproduced from [47]
Fig. 3A–B Typical example of an inhibition-type lateral flow assay:
A analyte in buffer, B analyte in spiked fruit juice. Reproduced from
[43] with permission from Elsevier
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microarray format and use a comparable assay format to
that outlined for NALFIA [46]. We suggest that such a
format where antibodies are used to capture labeled
amplicons should be called a nucleic acid microarray
immunoassay (NAMIA). In this format, the number of
discrete targets can be easily expanded up to 10–15
different targets. The results of this approach, a 30 min
amplification followed by a one-step incubation on the
microarray for 1 h, can be obtained by automated data
processing following the digitization of the spots by flatbed
scanning or digital photography (10 min of processing time
in total). A scheme showing the principle of a NALFIA,
NALMIA, or NAMIA is depicted in Fig. 5.
Applications of lateral flow microarray immunoassay
formats (LMIA)
A new approach is to print an antibody microarray onto a
lateral flow strip, thus combining the advantages of nucleic
acid lateral flow immunoassays (NALFIA) and nucleic acid
microarray immunoassays (NAMIA) [52, 53]. Again, when
antibodies are used to capture tagged amplicons, the format
is referred to as a nucleic acid lateral flow microarray
immunoassay (NALMIA). In this format, more antibodies
can be spotted than on a “classical” LFA strip, so more
target molecules/microorganisms can be detected simulta-
neously. Since the reaction time is similar to that needed for
the conventional lateral flow assay (5–10 min), this format
is much quicker than the general antibody microarray
format on slides, which may take 2–4 h to yield the final
results. A recent example in which specific amplicons of
virulence factors of Shiga toxin-producing Escherichia coli
were applied is shown in Fig. 6 (unpublished results).
Fig. 5 Scheme for a NALFIA,
NAMIA, or NALMIA. Neutra-
vidin adsorbed onto CNPs
detects biotin-labeled ampli-
cons; the discriminating tag is
recognized by its respective an-
tibody, which is immobilized
onto nitrocellulose membranes
or pads
Fig. 6 A lateral flow microarray immunoassay (LMIA) test showing
double-labeled amplicons specific for virulence factors of Shiga toxin
producing Escherichia coli. Left panel: layout of the LMIA. Right
panel: typical example of a double-labeled (tag/biotin) amplicon
solution, and detection using neutravidin-coated carbon nanoparticles
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Applications in other formats
Mouse immunoglobulin isotyping, the detection of
human serum albumin (HSA), and the determination of
Kunitz-type trypsin inhibitor from soy (KSTI) were reported
in [9] using a nitrocellulose strip with spots of specific
antibodies or antigens and incubation of the nitrocellulose
strips in 1 mL volumes.
Upon adsorbing carboxyfluorescein (FAM)-labeled
ssDNA onto CNPs, the fluorescence is quenched. This
phenomenon was used to develop an assay format in which
the hybridization of DNA strands complementary to the FAM-
labeled ssDNA released the FAM label from the CNPs, thus
restoring fluorescence [17]. As a proof of principle,
sequences from HIV were labeled with FAM. Binding to
CNPs quenched the fluorescence. Following hybridization
with the complementary sequence, the fluorescence was
restored.
Another approach was described in [18], where a
fluorescently labeled DNA sequence does not bind to
CNPs in the presence of Hg2+ions, because the induced
hairpin structure formed by thymidine–Hg2+–thymidine
prevents binding. The fluorescent properties of the DNA
are retained. In the absence of Hg2+ ions, the DNA binds to
the CNPs, which results in the quenching of the fluores-
cence. The same principle was used to detect Ag+ ions in
solution [54]. In all cases, the fluorescence was measured
using a fluorometer. The LODs were very low (10 nM to
500 pM), showing good sensitivity and reproducibility.
Although the preparation of fluorescent, phosphorescent,
or up-converting carbon nanoparticles has been reported,
none of these methods have yet been used as detection
labels in diagnostic assays. The question remains as to
whether it will be possible to functionalize such CNPs with
biomolecules while retaining their fluorescent, chemilumi-
nescent, up-converting, or phosphorescent properties.
Commercialization
SB4-derived CNPs are being applied and commercialized
by the company Genzyme Diagnostics (Cambridge, MA,
USA; http://www.genzyme.com/), which was recently
acquired by Sekisui Diagnostics (West Malling, UK;
http://www.sekisuidiagnostics.com/), and by the company
Oxoid (Cambridge, UK; http://www.oxoid.com/uk/blue/
index.asp) for their syphilis agglutination test.
The company Vivacta (http://www.vivacta.com/) is
applying and commercializing carbon nanoparticles in a
format using a piezoelectric film for signal readout [55].
The companyMaiia is commercializing carbon nanostrings
(http://www.maiiadiagnostics.com/products/carbon_black_
nano-strings/).
Conclusions
CNPs prepared from soot—amorphous carbon produced in
bulk quantities, with the properties outlined in patents
US5529901A1 [10] and US5641689A1 [11], e.g., SB4—
can be used satisfactorily as versatile labels in lateral flow
and microarray immunoassay test formats. They provide a
less expensive yet more sensitive and stable alternative to
other labels. The signal can be read easily by visual
inspection (black on a white background), and can be
quantified using a flatbed scanner and image analysis
software.
CNPs not obtained from soot intended for bulk applica-
tions, such as in ink, toner or tires, are often prepared on the
small scale in laboratories. Only a few applications with
these “homemade” nanoparticles have been reported at the
time of writing. Hence, their applicability is still question-
able. Luminescent CNPs need more sophisticated (and
often more expensive) equipment to visualize and quantify
the test results.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
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